Hester Biosciences Limited — Investor Meet, 04-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Hester Biosciences' Q1 FY'26 saw mixed results: standalone sales were INR63 Cr, down 14% with PAT declining 7%, mainly due to delayed government immunization programs for Animal Health. However, consolidated PAT grew over 100% driven by a strong turnaround in Africa operations, which posted a INR5 Cr profit on INR17 Cr sales. Management is optimistic for FY'26, expecting delayed orders to normalize from Q2. Petcare and Poultry segments (2% growth this quarter) are gaining momentum. The Avian Influenza vaccine launch awaits regulatory clearance. The BSL-3 facility, with INR176 Cr work in progress, is being repurposed for animal vaccines. The overall tone is confident, with strategic focus on efficiency, international expansion, and new product development.